南方医科大学药理学教授，博士生导师。主要从事高尿酸血症/痛风的发病机制及降尿酸药物靶点及药物发现研究。担任全国卫生产业企业管理协会转化医学产业分会常务理事、广东省药理学会常务理事、广东省药理学会药物筛选与评价专业委员会主任委员和广东省药理学会内分泌代谢病药理专业委员会、药物毒理专业委员会副主任委员。先后主持国家自然科学基金6项，广东省科技计划项目和广州市科民生科技攻关计划等5项，国内外企业委托新药研发项目10多项。在J Med Chem, Acta Pharmacol Sin, Eur J Med Chem, Phytomedicine, Bioorg Chem, J Org Chem等期刊发表论文100多篇，发明专利10多项。

主要从事高尿酸血症/痛风的发病机制及降尿酸药物靶点及药物发现研究

1.Zhao Z, Luo J, Liao H, Zheng F, Chen X, Luo J, Chen Y, Zhao K, Zhang S, Tian J, Wu T, Li Y, Li L, Yang Y, Lin C, Zhang Q, Tian Y, Pang J. Pharmacological evaluation of a novel skeleton compound isobavachin (4',7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity. Bioorg Chem 2023, 133:106405.

2.Zhao ZA, Jiang Y, Chen YY, Wu T, Lan QS, Li YM, Li L, Yang Y, Lin CT, Cao Y, Zhou PZ, Guo JY, Tian YX, Pang JX. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacol Sin 2022, 43(7):1884-1884.

3. Zhao Z, Liu J, Yuan L, Yang ZC, Kuang PH, Liao H, Luo J, Feng HC, Zheng FX, Chen YJ, Wu T, Guo JY, Cao Y, Yang Y, Lin CT, Zhang Q, Chen JJ, Pang JX. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents. Eur J Med Chem 2022, 242.

4. Zhao Z, Liu J, Kuang PH, Luo J, Surineni G, Cen XL, Wu T, Cao Y, Zhou PZ, Pang JX, Zhang Q, Chen JJ. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia. Eur J Med Chem 2022, 229.

5. Li YM, Zhao ZA, Luo J, Jiang YQ, Li L, Chen YY, Zhang LQ, Huang QH, Cao Y, Zhou PZ, Wu T, Pang JX. Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. Phytomedicine 2021, 87.